Early multidisciplinary daily geriatric care reduces in-hospital mortality and medical complications in elderly patients with hip fracture, but there is not a significant effect on length of hospital stay or long-term functional recovery.

After completing this course, the reader will be able to:1. Use patient age as only one consideration, along with tumor status and comorbidities, in deciding on treatment strategies for elderly colorectal cancer patients.2. Obtain and apply information regarding the medical, functional, mental, and social status of colorectal cancer elderly patients in order to make appropriate therapeutic decisions.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTPurpose. To analyze differences in the therapeutic approach to and tumor-related mortality of young and elderly colorectal cancer (CRC) patients. Patients and Methods. This was a descriptive study of a retrospective cohort, based on administrative databases, of all patients with CRC diagnosed or treated in our institution. We extracted data on sociodemographic characteristics, comorbidity, type of cancer, type of treatment received, survival time, and cause of death. We compared differences between a young group (YG) (age <75 years) and an older group (OG) (age >75 years) and assessed the variables associated with receiving different therapeutic options (multivariate analysis) and with survival time (Cox proportional hazards models).Results. The study included 503 patients (YG, 320; OG, 183), with mean ages of 63.1 years in the YG and 81.8 years in the OG. No differences were observed between the groups in degree of differentiation, extension, tumor stage, or comorbidity. After adjustment for gender, comorbidity, and tumor localization and extension, YG patients were more likely than OG patients to receive surgery, radiotherapy, and chemotherapy and less likely to receive palliative care. After a median follow-up of 36.5 months, YG patients had a longer tumor-specific survival time than OG patients (36.41 months vs 26.05 months). After further adjustment, the YG had a lower tumor-specific mortality risk (hazard ratio, 0.66) than the OG.Conclusion. In comparison with younger patients, elderly CRC patients are undertreated, mainly because of their age and not because of their tumor type or comorbidity. Elderly patients have a significantly shorter tumor-specific survival time, partially because of this undertreatment.

No abstract

This study characterizes the early steps of T lymphocyte activation in elderly subjects. The expression of CD69, the earliest inducible antigen which appears with T lymphocyte activation, was assessed in T cells cultured with medium, anti-CD3 or PMA. The proliferative responses of T cells stimulated through CD69 and CD3 pathways were also studied. Donors included 31 healthy elderly [age mean (SD) 80(8) years] and 33 healthy young [age 30(5) years] subjects. In elderly people, the expression of CD69 was lower in T cells cultured with medium [3.4% (1.65-5.9; 25-75 percentiles) vs. 10% (6-18), p < 0.0003] and anti-CD3 activated [28.1% (16.5-53.8) vs. 79.5% (73-89), p < 0.0002] T cells. With PMA at 10 ng/ml, CD69 expression was higher in both groups of T cells, though still lower in the aged [84.5% (70.9-94.9) vs. 99% (65.7-100), p = 0.051]. CD69 T cells expression was equal in both groups with 2 ng/ml of PMA, but the co-stimulatory responses to CD69 under these conditions and in the presence of anti-CD3 were lower in the aged (16914 vs. 28904 cpm, p < 0.02) and (6944 vs. 14370 cpm, p < 0.02) respectively. Aged T cells failed to express CD25 at the same levels of young T cells when stimulated with CD69. These results suggests an age-associated defect in the very early steps of T lymphocyte activation that might influence later stages of lymphocyte function. An alteration in the transmission of the activation signal from the cell surface to protein kinase C may play a primary role in this defect.

BackgroundThe Activity in GEriatric acute CARe (AGECAR) is a randomised control trial to assess the effectiveness of an intrahospital strength and walk program during short hospital stays for improving functional capacity of patients aged 75 years or older.Methods/DesignPatients aged 75 years or older admitted for a short hospital stay (≤14 days) will be randomly assigned to either a usual care (control) group or an intervention (training) group. Participants allocated in the usual care group will receive normal hospital care and participants allocated in the intervention group will perform multiple sessions per day of lower limb strength training (standing from a seated position) and walking (10 min bouts) while hospitalized. The primary outcome to be assessed pre and post of the hospital stay will be functional capacity, using the Short Physical Performance Battery (SPPB), and time to walk 10 meters. Besides length of hospitalization, the secondary outcomes that will also be assessed at hospital admission and discharge will be pulmonary ventilation (forced expiratory volume in one second, FEV1) and peripheral oxygen saturation. The secondary outcomes that will be assessed by telephone interview three months after discharge will be mortality, number of falls since discharge, and ability to cope with activities of daily living (ADLs, using the Katz ADL score and Barthel ADL index).DiscussionResults will help to better understand the potential of regular physical activity during a short hospital stay for improving functional capacity in old patients. The increase in life expectancy has resulted in a large segment of the population being over 75 years of age and an increase in hospitalization of this same age group. This calls attention to health care systems and public health policymakers to focus on promoting methods to improve the functional capacity of this population.Trial registrationClinicalTrials.gov ID: NCT01374893.